EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC 4.0

Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single‐Center Japanese Retrospective Cohort Study

Inzidenz, klinische Merkmale, Management und Outcomes hämatologischer immunvermittelter unerwünschter Ereignisse unter Immun-Checkpoint-Inhibitoren: retrospektive Kohortenstudie in einem japanischen Zentrum

Ryo Yoshimaru iD, Hirotaka Nakamura, Yong-Mei Guo, Kensuke Matsuda, Tetsuya Sakai iD, Yoshitaka Zenke, Kiyotaka Yoh, Kohei Shitara iD, Nobuaki Matsubara iD, Kenichi Harano iD, Hiromichi Nakajima iD, Nobuyuki Takahashi iD und 7 weitere

Cancer Medicine · 2026-10 · 15 (10)

DOI: 10.1002/cam4.72337 ↗

Auf einen Blick

Bei 3371 mit ICI behandelten Patient:innen traten bei 40 hämatologische irAEs auf (1,2 %). Am häufigsten war immunthrombozytopenie; 85,0 % der Ereignisse waren Grad 3 oder höher.

Fragestellung

Wie häufig treten hämatologische irAEs unter ICI auf, und wie sind klinische Merkmale, Management und Outcomes in einer japanischen Einzelszentrums-Kohorte?

Methode

Retrospektive Einzelszentrums-Kohortenstudie; Identifikation potenzieller Fälle per Diagnosesuche, Knochenmarkbefunden und DAT; Chart-Review zum Ausschluss anderer Ursachen.

Ergebnisse

Von 3371 Patient:innen mit ICI-Regimen entwickelten 40 eine heme-irAE (1,2 %). Median bis zum Beginn: 12 Wochen. Steroide bei 25, hämatologische Besserung bei 18; Wiederaufnahme/Fortsetzung der Tumortherapie bei 20 ohne Rezidiv im Follow-up.

Einschränkungen

Einzelszentrumsstudie; deskriptiver Vergleich zur Onset-Zeit mit wenigen Fällen; explorative Analysen zu Dual-ICI, Überleben und weiterer ICI-Therapie.

Schlussfolgerung der Autor:innen

Heme-irAEs waren selten, aber häufig schwer. Ihr Auftreten war mit einer längeren Unterbrechung der Krebstherapie verbunden; frühe Erkennung, sorgfältige Diagnostik und multidisziplinäres Management sind wichtig.

Kernaussagen

  • Hämatologische irAEs traten bei 1,2 % der 3371 Patient:innen auf.
  • Am häufigsten war immunthrombozytopenie; 85,0 % waren Grad 3 oder höher.
  • Steroide führten bei 18 von 25 Patient:innen zu hämatologischer Besserung.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 06.10.2026. Verfasst von Ryo Yoshimaru und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Hematologic Diseases, Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune‐related adverse events (irAEs) are complications associated with immune checkpoint inhibitors (ICIs). Hematologic irAEs (heme‐irAEs) are rare but potentially serious and may interfere with cancer treatment. However, their clinical characteristics remain insufficiently described.

Methods

We conducted a single‐center retrospective study using the National Cancer Center Hospital East medical database from April 1, 2014, to March 31, 2024. Potential heme‐irAE cases were identified using diagnostic name searches, bone marrow examination records, and positive DAT results and were followed by chart review to exclude alternative etiologies, such as chemotherapy‐related myelosuppression, marrow involvement, infection, and hematologic malignancy.

Results

Of the 3371 patients treated with ICI‐containing regimens, 40 patients developed heme‐irAEs, indicating an observed incidence of 1.2%. The most common heme‐irAE reported was immune thrombocytopenia, and 85.0% of these events were Grade 3 or higher. The median time from ICI initiation to heme‐irAE onset was 12 weeks. For all affected patients included in the regimen‐specific onset‐time comparison, the median time to heme‐irAE onset appeared shorter with dual ICI therapy without chemotherapy than with ICI monotherapy, although this descriptive comparison was based on a small number of cases. ICI‐containing regimens were interrupted or discontinued in most patients, and systemic corticosteroids were administered to 25 patients, 18 of whom achieved hematologic improvement. Cancer treatment was resumed or continued for 20 patients, with no recurrent heme‐irAEs observed during the follow‐up period. In an exploratory landmark analysis, hematologic response was associated with longer survival after heme‐irAE onset.

Conclusion

Heme‐irAEs were rare but frequently severe in this Japanese single‐center cohort. Their occurrence was associated with prolonged interruption of cancer treatment, underscoring the importance of early recognition, careful diagnostic evaluation, and multidisciplinary management of heme‐irAEs. Our findings regarding dual ICI therapy, survival, and subsequent ICI therapy after heme‐irAE onset should be interpreted as exploratory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsHematologic DiseasesImmune Checkpoint InhibitorsNeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedIncidenceJapanRetrospective Studies

Stichwörter der Autor:innen

drug‐related adverse reactionsimmune checkpoint inhibitors/adverse effectsimmunosuppressive agentstreatment outcome

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hematology and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Internal Medicine, Minamiakatsuka Clinic, Mito, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

ORCID-Profile: Ryo Yoshimaru, Tetsuya Sakai, Kohei Shitara, Nobuaki Matsubara, Kenichi Harano, Hiromichi Nakajima, Nobuyuki Takahashi, Masafumi Ikeda, Takao Fujisawa, Junichiro Yuda

Zitieren

APA

Yoshimaru, R., Nakamura, H., Guo, Y. M., Matsuda, K., Sakai, T., Zenke, Y., Yoh, K., Shitara, K., Matsubara, N., Harano, K., Nakajima, H., Takahashi, N., Ikeda, M., Fujisawa, T., Nakamura, S., Akie, K., Ito, M., Wakabayashi, M., & Yuda, J. (2026). Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single‐Center Japanese Retrospective Cohort Study. Cancer Medicine, 15(10). https://doi.org/10.1002/cam4.72337

Vancouver

Yoshimaru R, Nakamura H, Guo YM, Matsuda K, Sakai T, Zenke Y, et al. Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single‐Center Japanese Retrospective Cohort Study. Cancer Medicine. 2026;15(10). doi:10.1002/cam4.72337

BibTeX
@article{Yoshimaru2026,
  author = {Yoshimaru, Ryo and Nakamura, Hirotaka and Guo, Yong-Mei and Matsuda, Kensuke and Sakai, Tetsuya and Zenke, Yoshitaka and Yoh, Kiyotaka and Shitara, Kohei and Matsubara, Nobuaki and Harano, Kenichi and Nakajima, Hiromichi and Takahashi, Nobuyuki and Ikeda, Masafumi and Fujisawa, Takao and Nakamura, Saki and Akie, Kenta and Ito, Masayuki and Wakabayashi, Masashi and Yuda, Junichiro},
  title = {Incidence, Clinical Characteristics, Management, and Outcomes of Hematologic Immune‐Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Single‐Center Japanese Retrospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {10},
  doi = {10.1002/cam4.72337}
}
Kostenlos starten →